Steve O’Brien

591 total citations
7 papers, 461 citations indexed

About

Steve O’Brien is a scholar working on Virology, Immunology and Genetics. According to data from OpenAlex, Steve O’Brien has authored 7 papers receiving a total of 461 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Virology, 4 papers in Immunology and 3 papers in Genetics. Recurrent topics in Steve O’Brien's work include HIV Research and Treatment (4 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Immune Cell Function and Interaction (3 papers). Steve O’Brien is often cited by papers focused on HIV Research and Treatment (4 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Immune Cell Function and Interaction (3 papers). Steve O’Brien collaborates with scholars based in France, United States and United Kingdom. Steve O’Brien's co-authors include Jean‐François Zagury, Cheryl A. Winkler, Daniel Zagury, Mary Carrington, Houria Hendel, George W. Nelson, Jay Rappaport, Hélène Le Buanec, Jean‐Marie Andrieu and Sophie Caillat‐Zucman and has published in prestigious journals such as Blood, The Journal of Immunology and JAIDS Journal of Acquired Immune Deficiency Syndromes.

In The Last Decade

Steve O’Brien

7 papers receiving 456 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Steve O’Brien France	6	228	209	160	128	117	7	461
Per-Anders Broliden Sweden	6	162 0.7×	254 1.2×	58 0.4×	247 1.9×	9 0.1×	7	559
Kate Jones Australia	9	311 1.4×	230 1.1×	41 0.3×	28 0.2×	9 0.1×	19	469
Lyda M. Osorio Sweden	11	138 0.6×	265 1.3×	39 0.2×	123 1.0×	8 0.1×	15	565
Dominic Dordai United States	5	144 0.6×	243 1.2×	23 0.1×	26 0.2×	15 0.1×	9	452
Susanne Spira United States	9	134 0.6×	34 0.2×	116 0.7×	50 0.4×	9 0.1×	11	419
Phyllis A. Kirchner United States	7	43 0.2×	153 0.7×	130 0.8×	57 0.4×	7 0.1×	12	325
B Sadat-Sowti France	6	140 0.6×	284 1.4×	54 0.3×	21 0.2×	7 0.1×	8	355
K M Crassi United States	7	55 0.2×	473 2.3×	49 0.3×	11 0.1×	31 0.3×	8	568
Joanne Yetz United States	8	93 0.4×	203 1.0×	43 0.3×	17 0.1×	13 0.1×	9	371
D. Chandanayingyong Thailand	11	24 0.1×	155 0.7×	85 0.5×	21 0.2×	29 0.2×	28	316

Countries citing papers authored by Steve O’Brien

Since Specialization

Citations

This map shows the geographic impact of Steve O’Brien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steve O’Brien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steve O’Brien more than expected).

Fields of papers citing papers by Steve O’Brien

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steve O’Brien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steve O’Brien. The network helps show where Steve O’Brien may publish in the future.

Co-authorship network of co-authors of Steve O’Brien

This figure shows the co-authorship network connecting the top 25 collaborators of Steve O’Brien. A scholar is included among the top collaborators of Steve O’Brien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steve O’Brien. Steve O’Brien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Alonso‐Domínguez, Juan Manuel, Jacob Grinfeld, Mary Alikian, et al.. (2012). PTCH1 Expression At Diagnosis Reliably Predicts Treatment Failure in Imatinib-Treated Chronic Myeloid Leukaemia Patients. Blood. 120(21). 875–875. 1 indexed citations

2.

Roy, Lydia, Joëlle Guilhot, Tillmann Krahnke, et al.. (2006). Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood. 108(5). 1478–1484. 157 indexed citations

3.

Guilhot, François, Lydia Roy, Joëlle Guilhot, et al.. (2005). Retrospective Comparison of Imatinib Versus Interferon Plus Cytarabine (IFN/Ara-c) for Chronic Myelogenous Leukemia (CML) Patients in Chronic Phase (CP).. Blood. 106(11). 165–165. 5 indexed citations

4.

Yang, Otto O., W. John Boscardin, Jose L. Matud, et al.. (2002). Immunologic Profile of Highly Exposed Yet HIV Type 1-Seronegative Men. AIDS Research and Human Retroviruses. 18(14). 1051–1065. 33 indexed citations

5.

Hendel, Houria, Cheryl A. Winkler, Ping An, et al.. (2001). Validation of Genetic Case-Control Studies in AIDS and Application to the CX3CR1 Polymorphism. JAIDS Journal of Acquired Immune Deficiency Syndromes. 26(5). 507–511. 18 indexed citations

6.

Hendel, Houria, Cheryl A. Winkler, Ping An, et al.. (2001). Validation of Genetic Case-Control Studies in AIDS and Application to the CX3CR1 Polymorphism. JAIDS Journal of Acquired Immune Deficiency Syndromes. 26(5). 507–511. 9 indexed citations

7.

Hendel, Houria, Sophie Caillat‐Zucman, Hélène Le Buanec, et al.. (1999). New Class I and II HLA Alleles Strongly Associated with Opposite Patterns of Progression to AIDS. The Journal of Immunology. 162(11). 6942–6946. 238 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact